AstraZeneca says its COVID-19 vaccine could be around 90% effective, potentially cheaper to make and easier to distribute than rivals. The British drug-maker on Monday said it will have as many as 200 million doses by the end of this year – around four times as many as U.S. competitor Pfizer. Seven hundred million doses could be ready globally as soon as the end of the first quarter of 2021. According to data from late-stage trials in Britain and Brazil, the vaccine was 90% effective in preventing COVID-19 when it was administered as a half dose followed by a full dose at least a month later. AstraZeneca said no serious safety events were confirmed. “We’re extremely excited because, well, the data is shown us is that the vaccine is clearly effective in terms of reducing infections. It’s clearly effective in terms of reducing people getting sick and going to hospital. It’s potentially reducing transmission and I think is it’s got every chance of being a very successful, very effective vaccine that can get us back to normal,” Dr. Mene Pangalos, Executive Vice President at AstraZeneca told the BBC.